hydroxyzine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diphenylmethyl piperazine derivatives 1400 68-88-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • hydroxyzine pamoate
  • hydroxizine
  • hydroxyzin
  • hydroxyzyne
  • tranquizine
  • hydroxyzine
  • hydroxyzine hydrochloride
  • hydroxyzine dihydrochloride
  • hydroxyzine HCl
A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.
  • Molecular weight: 374.91
  • Formula: C21H27ClN2O2
  • CLOGP: 4
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 35.94
  • ALOGS: -3.61
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
75 mg O
75 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 700 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 15.24 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 12, 1956 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 611.74 9.65 830 57699 145090 46482443
Intentional overdose 315.84 9.65 398 58131 64546 46562987
Toxicity to various agents 294.30 9.65 748 57781 211018 46416515
Intentional self-injury 285.31 9.65 239 58290 23927 46603606
Pruritus 226.00 9.65 742 57787 241610 46385923
Urticaria 216.64 9.65 465 58064 117427 46510106
Drug abuse 153.66 9.65 281 58248 63127 46564406
Rheumatoid arthritis 151.46 9.65 56 58473 240159 46387374
Poisoning 142.04 9.65 127 58402 13867 46613666
Poisoning deliberate 118.31 9.65 90 58439 7836 46619697
Chronic spontaneous urticaria 107.67 9.65 36 58493 505 46627028
Respiratory arrest 101.75 9.65 165 58364 33651 46593882
Cardio-respiratory arrest 99.48 9.65 227 58302 59642 46567891
Electrocardiogram QT prolonged 94.75 9.65 203 58326 51122 46576411
Cardiac arrest 93.26 9.65 287 58242 90112 46537421
Anticholinergic syndrome 85.87 9.65 43 58486 1763 46625770
Treatment failure 82.23 9.65 10 58519 93077 46534456
Suicide attempt 74.65 9.65 193 58336 54843 46572690
Angioedema 70.76 9.65 154 58375 39188 46588345
Suicidal ideation 66.71 9.65 188 58341 56194 46571339
Joint swelling 66.55 9.65 66 58463 166007 46461526
Anxiety 66.03 9.65 422 58107 181535 46445998
Contraindicated product administered 64.99 9.65 11 58518 79936 46547597
Burning mouth syndrome 61.27 9.65 22 58507 386 46627147
Overdose 56.90 9.65 266 58263 101713 46525820
Somnolence 54.31 9.65 359 58170 156162 46471371
Drug dependence 53.04 9.65 92 58437 19809 46607724
Synovitis 50.54 9.65 8 58521 61067 46566466
Drug intolerance 48.65 9.65 68 58461 146981 46480552
Chemical submission 47.12 9.65 16 58513 236 46627297
Bradypnoea 46.44 9.65 35 58494 3004 46624529
Irritability 46.12 9.65 108 58421 28838 46598695
Drug reaction with eosinophilia and systemic symptoms 43.58 9.65 107 58422 29441 46598092
Victim of chemical submission 41.32 9.65 15 58514 272 46627261
Prescription form tampering 40.83 9.65 19 58510 661 46626872
Rash maculo-papular 38.04 9.65 98 58431 27776 46599757
Allergy test positive 35.56 9.65 14 58515 320 46627213
Plasma cell myeloma 34.26 9.65 7 58522 44471 46583062
Coma 33.85 9.65 154 58375 58195 46569338
Hallucination, gustatory 31.69 9.65 9 58520 70 46627463
Scratch 30.54 9.65 34 58495 4828 46622705
Skin plaque 30.30 9.65 37 58492 5798 46621735
Faecal vomiting 29.75 9.65 15 58514 624 46626909
Drug screen positive 29.38 9.65 30 58499 3861 46623672
Hereditary angioedema 28.68 9.65 35 58494 5481 46622052
Mastocytosis 28.63 9.65 13 58516 427 46627106
Exposure via ingestion 28.51 9.65 28 58501 3439 46624094
Systemic lupus erythematosus 28.34 9.65 24 58505 65156 46562377
Eczema 28.12 9.65 72 58457 20328 46607205
Miosis 27.96 9.65 38 58491 6619 46620914
Psoriasis 27.04 9.65 180 58349 78424 46549109
Glossodynia 26.82 9.65 11 58518 44362 46583171
Intentional product misuse 26.31 9.65 123 58406 47005 46580528
Urticaria thermal 25.78 9.65 8 58521 87 46627446
Drug hypersensitivity 25.01 9.65 437 58092 243388 46384145
Agitation 24.87 9.65 136 58393 55279 46572254
Asphyxia 24.83 9.65 32 58497 5294 46622239
Therapeutic product effect decreased 24.60 9.65 41 58488 82560 46544973
Drug ineffective 24.59 9.65 655 57874 677183 45950350
Insomnia 24.48 9.65 315 58214 164609 46462924
Blood immunoglobulin E increased 23.99 9.65 19 58510 1754 46625779
Long QT syndrome 23.71 9.65 24 58505 3056 46624477
Arthropathy 23.46 9.65 44 58485 84656 46542877
Mixed liver injury 23.31 9.65 24 58505 3119 46624414
Abdominal discomfort 23.17 9.65 104 58425 151061 46476472
Altered state of consciousness 23 9.65 73 58456 23275 46604258
Alcoholism 22.24 9.65 20 58509 2198 46625335
Psychotic symptom 22.24 9.65 14 58515 896 46626637
Diet failure 22.06 9.65 6 58523 39 46627494
Hepatocellular injury 21.88 9.65 84 58445 29438 46598095
Decreased eye contact 21.42 9.65 7 58522 91 46627442
Labile hypertension 20.98 9.65 11 58518 497 46627036
Kounis syndrome 20.98 9.65 15 58514 1187 46626346
Mydriasis 20.92 9.65 43 58486 10510 46617023
Binge eating 20.92 9.65 10 58519 370 46627163
Depressed level of consciousness 20.84 9.65 116 58413 47453 46580080
Toxic skin eruption 20.59 9.65 47 58482 12340 46615193
Serotonin syndrome 20.54 9.65 72 58457 24148 46603385
Disturbance in attention 20.35 9.65 86 58443 31474 46596059
Nodular rash 19.99 9.65 8 58521 191 46627342
Interstitial lung disease 19.84 9.65 23 58506 53926 46573607
Lymphomatoid papulosis 19.70 9.65 7 58522 119 46627414
Panic attack 19.68 9.65 63 58466 20179 46607354
Perfume sensitivity 19.54 9.65 11 58518 573 46626960
Ventricular fibrillation 19.53 9.65 44 58485 11452 46616081
Atrial fibrillation 19.23 9.65 66 58463 103524 46524009
Urticaria chronic 19.17 9.65 10 58519 447 46627086
Eosinophilia 18.85 9.65 60 58469 19157 46608376
Pneumonia 18.63 9.65 346 58183 375974 46251559
Pancreatitis 18.20 9.65 105 58424 43522 46584011
Withdrawal syndrome 18.14 9.65 57 58472 18077 46609456
General physical health deterioration 18.12 9.65 79 58450 115690 46511843
Arthralgia 18.12 9.65 335 58194 364268 46263265
Aggression 17.92 9.65 66 58463 22678 46604855
Infusion related reaction 17.78 9.65 66 58463 101142 46526391
Akathisia 17.18 9.65 33 58496 7681 46619852
Respiratory depression 17.09 9.65 42 58487 11558 46615975
Hyperleukocytosis 16.96 9.65 9 58520 417 46627116
Maternal exposure during pregnancy 16.65 9.65 69 58460 102480 46525053
Hepatic enzyme increased 16.65 9.65 50 58479 81737 46545796
C-reactive protein increased 16.61 9.65 30 58499 58560 46568973
Congenital musculoskeletal anomaly 16.55 9.65 9 58520 438 46627095
Accidental overdose 16.46 9.65 59 58470 20007 46607526
Cholestasis 16.36 9.65 72 58457 26821 46600712
Pericarditis 16.04 9.65 5 58524 23922 46603611
Off label use 15.61 9.65 360 58169 379481 46248052
Renal impairment 15.48 9.65 45 58484 74327 46553206
Activation syndrome 15.44 9.65 7 58522 229 46627304
Accidental death 15.43 9.65 15 58514 1820 46625713
Derailment 15.23 9.65 5 58524 66 46627467
Depression 15.03 9.65 298 58231 169806 46457727
Dysarthria 14.83 9.65 89 58440 37409 46590124
Talipes 14.73 9.65 13 58516 1394 46626139
Neutropenia 14.72 9.65 112 58417 143092 46484441
Wrong technique in device usage process 14.64 9.65 15 58514 1938 46625595
Pleural effusion 14.63 9.65 54 58475 82898 46544635
Fat necrosis 14.49 9.65 9 58520 563 46626970
Anaemia 14.30 9.65 230 58299 255549 46371984
Formication 14.27 9.65 21 58508 3935 46623598
Pneumonitis 14.25 9.65 9 58520 28411 46599122
Temperature intolerance 13.92 9.65 30 58499 7577 46619956
Multiple fractures 13.88 9.65 25 58504 5542 46621991
Breast adenoma 13.77 9.65 4 58525 34 46627499
Cold agglutinins positive 13.77 9.65 4 58525 34 46627499
Tonsillar hypertrophy 13.74 9.65 10 58519 814 46626719
Photosensitivity reaction 13.53 9.65 41 58488 12751 46614782
Hypertriglyceridaemia 13.44 9.65 25 58504 5679 46621854
Burnout syndrome 13.39 9.65 6 58523 191 46627342
Superior sagittal sinus thrombosis 13.37 9.65 10 58519 848 46626685
Postural orthostatic tachycardia syndrome 13.33 9.65 9 58520 649 46626884
Red blood cell sedimentation rate increased 13.31 9.65 6 58523 22883 46604650
Lower respiratory tract infection 13.24 9.65 31 58498 55058 46572475
Nasal oedema 13.23 9.65 10 58519 862 46626671
Osteonecrosis 13.12 9.65 8 58521 25736 46601797
Sleep disorder 13.10 9.65 102 58427 46693 46580840
Wound 12.97 9.65 21 58508 42781 46584752
Retrograde amnesia 12.96 9.65 7 58522 336 46627197
Torsade de pointes 12.90 9.65 39 58490 12115 46615418
Affect lability 12.85 9.65 30 58499 7990 46619543
Gastrointestinal ischaemia 12.70 9.65 6 58523 216 46627317
Musculoskeletal stiffness 12.40 9.65 72 58457 97921 46529612
Cholecystitis chronic 12.40 9.65 35 58494 10464 46617069
Hypertonic bladder 12.39 9.65 17 58512 2987 46624546
Micrognathia 12.35 9.65 6 58523 230 46627303
Hallucination, olfactory 12.35 9.65 6 58523 230 46627303
Bruxism 12.33 9.65 17 58512 3000 46624533
Anaphylactic reaction 12.33 9.65 111 58418 53001 46574532
Eyelid haemangioma 12.24 9.65 3 58526 12 46627521
Hypercreatininaemia 11.89 9.65 7 58522 397 46627136
Bursitis 11.86 9.65 5 58524 19837 46607696
Gastrointestinal sounds abnormal 11.77 9.65 18 58511 3488 46624045
Herpes zoster meningoencephalitis 11.74 9.65 6 58523 257 46627276
Febrile neutropenia 11.73 9.65 70 58459 94557 46532976
Nasopharyngitis 11.68 9.65 130 58399 153868 46473665
Metabolic acidosis 11.68 9.65 86 58443 38694 46588839
Papule 11.63 9.65 20 58509 4275 46623258
Malignant neoplasm progression 11.62 9.65 42 58487 64884 46562649
Negative thoughts 11.51 9.65 9 58520 816 46626717
Granulomatous liver disease 11.50 9.65 9 58520 817 46626716
Drug withdrawal syndrome 11.48 9.65 66 58463 27318 46600215
Tachycardia 11.45 9.65 182 58347 99440 46528093
Apallic syndrome 11.39 9.65 8 58521 615 46626918
Haemoglobin decreased 11.38 9.65 105 58424 128844 46498689
Nightmare 11.31 9.65 46 58483 16552 46610981
Cardiac failure congestive 11.30 9.65 68 58461 91682 46535851
Dependence 11.27 9.65 13 58516 1918 46625615
Osteonecrosis of jaw 11.27 9.65 16 58513 34386 46593147
Therapeutic product effect incomplete 11.24 9.65 55 58474 78098 46549435
Vascular stent thrombosis 11.08 9.65 9 58520 862 46626671
Mucosal inflammation 11.00 9.65 20 58509 38956 46588577
Erythema marginatum 10.96 9.65 3 58526 20 46627513
Neuropathy peripheral 10.86 9.65 68 58461 90825 46536708
Occipital neuralgia 10.85 9.65 6 58523 302 46627231
Transverse sinus thrombosis 10.77 9.65 8 58521 672 46626861
Skin infection 10.76 9.65 35 58494 11304 46616229
Bipolar disorder 10.59 9.65 26 58503 7151 46620382
Electrocardiogram QRS complex prolonged 10.56 9.65 22 58507 5427 46622106
Pancytopenia 10.50 9.65 63 58466 84995 46542538
Generalised tonic-clonic seizure 10.49 9.65 64 58465 27058 46600475
Omphalitis 10.39 9.65 4 58525 86 46627447
Acarodermatitis 10.36 9.65 8 58521 712 46626821
Hair colour changes 10.35 9.65 12 58517 1780 46625753
Superior mesenteric artery syndrome 10.22 9.65 4 58525 90 46627443
Rash pustular 10.12 9.65 25 58504 6904 46620629
Infection 10.04 9.65 113 58416 133479 46494054
Alpha 2 globulin increased 9.94 9.65 4 58525 97 46627436
Post-traumatic stress disorder 9.87 9.65 18 58511 4030 46623503
Joint ankylosis 9.76 9.65 7 58522 557 46626976
Gastrointestinal haemorrhage 9.71 9.65 57 58472 77316 46550217
Injection site mass 9.71 9.65 41 58488 14999 46612534
Cerebral infarction 9.68 9.65 9 58520 23357 46604176

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 483.27 10.58 544 29391 98948 29823595
Toxicity to various agents 328.49 10.58 613 29322 176570 29745973
Drug abuse 94.77 10.58 235 29700 81837 29840706
Respiratory arrest 90.39 10.58 128 29807 29130 29893413
Poisoning 89.46 10.58 81 29854 11301 29911242
Pruritus 85.48 10.58 286 29649 117918 29804625
Coma 82.10 10.58 146 29789 40303 29882240
Intentional overdose 81.99 10.58 148 29787 41333 29881210
Cardio-respiratory arrest 67.06 10.58 165 29770 57141 29865402
Overdose 58.20 10.58 201 29734 84136 29838407
Suicidal behaviour 58.04 10.58 28 29907 1334 29921209
Urticaria 54.37 10.58 148 29787 54458 29868085
Parasomnia 52.28 10.58 17 29918 277 29922266
Ventricular tachyarrhythmia 51.89 10.58 17 29918 284 29922259
Hyperthermia 51.81 10.58 57 29878 10042 29912501
Bradypnoea 51.67 10.58 29 29906 1892 29920651
Exposure via ingestion 48.34 10.58 31 29904 2580 29919963
Cardiac arrest 45.80 10.58 199 29736 92651 29829892
Electrocardiogram QT prolonged 39.60 10.58 101 29834 35734 29886809
Toxic epidermal necrolysis 37.98 10.58 66 29869 17874 29904669
Drug reaction with eosinophilia and systemic symptoms 37.60 10.58 86 29849 28402 29894141
Intentional self-injury 37.12 10.58 56 29879 13476 29909067
Chemical submission 34.84 10.58 8 29927 30 29922513
Personal relationship issue 31.77 10.58 10 29925 146 29922397
Myocardial infarction 29.61 10.58 50 29885 125575 29796968
Febrile bone marrow aplasia 27.35 10.58 37 29898 8060 29914483
Eosinophilia 27.16 10.58 65 29870 22095 29900448
Electrocardiogram QRS complex prolonged 27.05 10.58 27 29908 4250 29918293
Shock 26.90 10.58 66 29869 22793 29899750
Somnolence 26.81 10.58 177 29758 96586 29825957
Dermatitis exfoliative 26.61 10.58 35 29900 7421 29915122
Anticholinergic syndrome 26.49 10.58 14 29921 810 29921733
Abnormal sleep-related event 26.33 10.58 12 29923 502 29922041
Face oedema 25.71 10.58 43 29892 11291 29911252
General physical health deterioration 25.23 10.58 38 29897 99906 29822637
Rash 24.87 10.58 297 29638 191592 29730951
Suspected suicide 23.86 10.58 22 29913 3139 29919404
Rheumatoid arthritis 23.64 10.58 6 29929 41191 29881352
Non-cardiogenic pulmonary oedema 22.99 10.58 12 29923 677 29921866
Bladder dilatation 22.87 10.58 15 29920 1297 29921246
Drug dependence 22.47 10.58 59 29876 21236 29901307
Dermatitis exfoliative generalised 22.05 10.58 20 29915 2795 29919748
Tachyphrenia 20.70 10.58 13 29922 1043 29921500
Sensory integrative dysfunction 20.45 10.58 5 29930 26 29922517
Emotional disorder of childhood 20.29 10.58 5 29930 27 29922516
Rash erythematous 19.54 10.58 58 29877 22394 29900149
Fixed eruption 19.34 10.58 13 29922 1171 29921372
Meningitis streptococcal 18.60 10.58 5 29930 40 29922503
Postural tremor 18.57 10.58 8 29927 292 29922251
Intentional product misuse 18.38 10.58 76 29859 34591 29887952
Clonus 18.21 10.58 17 29918 2464 29920079
Agitation 18.17 10.58 104 29831 53969 29868574
Tachycardia 18.11 10.58 131 29804 73608 29848935
Mumps 18.00 10.58 6 29929 106 29922437
Psoriasis 17.88 10.58 87 29848 42419 29880124
Mixed dementia 17.60 10.58 7 29928 208 29922335
Mental disorder 17.08 10.58 40 29895 13409 29909134
Alcoholism 17.04 10.58 19 29916 3395 29919148
Tremor 16.88 10.58 131 29804 75232 29847311
Agoraphobia 16.86 10.58 7 29928 233 29922310
Suicide attempt 16.81 10.58 77 29858 36620 29885923
Suicidal ideation 16.71 10.58 76 29859 36038 29886505
Drug ineffective 16.63 10.58 240 29695 340147 29582396
Eczema 16.15 10.58 39 29896 13330 29909213
Hypercapnic coma 15.59 10.58 6 29929 163 29922380
Victim of crime 15.51 10.58 7 29928 286 29922257
Atrial fibrillation 15.30 10.58 56 29879 108068 29814475
Disease progression 15.19 10.58 36 29899 79838 29842705
Faecal vomiting 15.18 10.58 8 29927 460 29922083
Neonatal respiratory distress 15.18 10.58 8 29927 460 29922083
Adrenergic syndrome 15.18 10.58 5 29930 85 29922458
Diarrhoea infectious 15.15 10.58 8 29927 462 29922081
Cerebral disorder 14.85 10.58 15 29920 2395 29920148
Accidental overdose 14.77 10.58 46 29889 18229 29904314
Injection site reaction 14.76 10.58 33 29902 10727 29911816
Administration related reaction 14.76 10.58 5 29930 93 29922450
Speech disorder developmental 14.75 10.58 11 29924 1168 29921375
Drug screen positive 14.67 10.58 20 29915 4387 29918156
Cardiac failure congestive 14.54 10.58 40 29895 84367 29838176
Echolalia 14.44 10.58 6 29929 200 29922343
Drug withdrawal syndrome 14.32 10.58 48 29887 19761 29902782
Pneumonia 14.20 10.58 242 29693 334064 29588479
Thyroiditis acute 14.20 10.58 5 29930 105 29922438
Prothrombin time ratio decreased 14.08 10.58 7 29928 356 29922187
Stereotypy 14.00 10.58 8 29927 540 29922003
Bicuspid aortic valve 13.65 10.58 6 29929 230 29922313
Generalised oedema 13.64 10.58 34 29901 11851 29910692
C-reactive protein increased 13.61 10.58 14 29921 43459 29879084
Priapism 13.54 10.58 20 29915 4723 29917820
Anxiety 13.37 10.58 143 29792 89728 29832815
Throat tightness 13.36 10.58 25 29910 7167 29915376
Dysuria 13.21 10.58 51 29884 22490 29900053
Adenoidectomy 13.20 10.58 4 29931 51 29922492
Miosis 13.18 10.58 26 29909 7750 29914793
Victim of homicide 13.09 10.58 5 29930 133 29922410
Respiratory failure 13.03 10.58 54 29881 100588 29821955
Disturbance in attention 12.92 10.58 50 29885 22079 29900464
Diarrhoea 12.88 10.58 246 29689 333857 29588686
Asphyxia 12.86 10.58 21 29914 5404 29917139
Meningioma 12.79 10.58 11 29924 1432 29921111
Anion gap 12.78 10.58 8 29927 638 29921905
Renal tubular disorder 12.72 10.58 20 29915 4986 29917557
Patient uncooperative 12.69 10.58 5 29930 145 29922398
Serotonin syndrome 12.62 10.58 43 29892 17848 29904695
Neurodevelopmental disorder 12.25 10.58 5 29930 159 29922384
Neurosis 12.22 10.58 5 29930 160 29922383
Cerebrovascular accident 11.96 10.58 43 29892 83434 29839109
Plasma cell myeloma 11.93 10.58 22 29913 53440 29869103
Dyskinesia 11.67 10.58 48 29887 21786 29900757
Erythrodermic psoriasis 11.58 10.58 8 29927 754 29921789
Bradycardia 11.55 10.58 108 29827 65418 29857125
Arthritis allergic 11.51 10.58 3 29932 21 29922522
Injection site mass 11.51 10.58 19 29916 4934 29917609
Kidney enlargement 11.41 10.58 8 29927 772 29921771
Pharyngeal dyskinesia 11.39 10.58 3 29932 22 29922521
Panic attack 11.22 10.58 26 29909 8655 29913888
Chronic spontaneous urticaria 10.78 10.58 4 29931 98 29922445
Acute myocardial infarction 10.76 10.58 23 29912 52916 29869627
Rash maculo-papular 10.67 10.58 52 29883 25366 29897177
Wrong patient received product 10.63 10.58 11 29924 1806 29920737

Pharmacologic Action:

SourceCodeDescription
ATC N05BB01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Diphenylmethane derivatives
ATC N05BB51 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Diphenylmethane derivatives
FDA MoA N0000000207 Histamine Receptor Antagonists
FDA EPC N0000175750 Antihistamine
CHEBI has role CHEBI:35474 minor tranquilisers
CHEBI has role CHEBI:37955 h1-receptor blockers
CHEBI has role CHEBI:50177 dermatological agent
CHEBI has role CHEBI:59683 anti-itching drug
CHEBI has role CHEBI:149553 anti-coronaviral agents
MeSH PA D000982 Antipruritics
MeSH PA D003879 Dermatologic Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Atopic dermatitis indication 24079001 DOID:3310
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Urticaria indication 126485001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Severe Pruritus off-label use
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Shock contraindication 27942005
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypothyroidism contraindication 40930008 DOID:1459
Third trimester pregnancy contraindication 41587001
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Multiple organ failure contraindication 57653000
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Open-angle glaucoma contraindication 84494001 DOID:1067
Seizure disorder contraindication 128613002
Cystic fibrosis contraindication 190905008 DOID:1485
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Sepsis syndrome contraindication 238150007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Continuous fever contraindication 271751000
Smoking cessation assistance contraindication 384742004
Angle-closure glaucoma contraindication 392291006 DOID:13550
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Smokes tobacco daily contraindication 449868002
Severe Hypoxemia contraindication
Theophylline Toxicity contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.53 Basic
pKa2 3.53 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 8.70 WOMBAT-PK CHEMBL
Cytochrome P450 2D6 Enzyme Ki 5.41 WOMBAT-PK
Envelope glycoprotein gp160 Unclassified IC50 5.20 CHEMBL

External reference:

IDSource
4019782 VUID
N0000147873 NUI
D00672 KEGG_DRUG
2192-20-3 SECONDARY_CAS_RN
4017874 VANDF
4017875 VANDF
4019782 VANDF
C0020404 UMLSCUI
CHEBI:5818 CHEBI
CHEMBL896 ChEMBL_ID
CHEMBL1201007 ChEMBL_ID
CHEMBL3186993 ChEMBL_ID
CHEMBL1200467 ChEMBL_ID
DB00557 DRUGBANK_ID
D006919 MESH_DESCRIPTOR_UI
7199 IUPHAR_LIGAND_ID
599 INN_ID
30S50YM8OG UNII
3658 PUBCHEM_CID
154987 RXNORM
4857 MMSL
4858 MMSL
4859 MMSL
6478 MMSL
7094 MMSL
d00907 MMSL
001451 NDDF
001452 NDDF
001453 NDDF
372856003 SNOMEDCT_US
80165005 SNOMEDCT_US
83933007 SNOMEDCT_US
83945003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vistaril HUMAN PRESCRIPTION DRUG LABEL 1 0069-5410 CAPSULE 25 mg ORAL NDA 15 sections
Vistaril HUMAN PRESCRIPTION DRUG LABEL 1 0069-5420 CAPSULE 50 mg ORAL NDA 15 sections
Vistaril HUMAN PRESCRIPTION DRUG LABEL 1 0069-5440 SUSPENSION 25 mg ORAL NDA 15 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5060 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5061 TABLET, FILM COATED 25 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5062 TABLET, FILM COATED 50 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1670 CAPSULE 25 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1671 CAPSULE 50 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1803 CAPSULE 25 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1804 CAPSULE 50 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-4822 SYRUP 10 mg ORAL ANDA 14 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0613 CAPSULE 25 mg ORAL ANDA 14 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0615 CAPSULE 50 mg ORAL ANDA 14 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0674 CAPSULE 25 mg ORAL ANDA 14 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-1617 TABLET, FILM COATED 25 mg ORAL ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-4201 INJECTION, SOLUTION 25 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-5601 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-5602 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-5610 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0555-0302 CAPSULE 50 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0555-0323 CAPSULE 25 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0555-0324 CAPSULE 100 mg ORAL ANDA 13 sections
Hydroxyzine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8082 TABLET 25 mg ORAL ANDA 12 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8356 CAPSULE 25 mg ORAL ANDA 13 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8357 CAPSULE 50 mg ORAL ANDA 13 sections
Hydroxyzine HUMAN PRESCRIPTION DRUG LABEL 1 0904-0357 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Hydroxyzine HUMAN PRESCRIPTION DRUG LABEL 1 0904-0358 TABLET, FILM COATED 25 mg ORAL ANDA 13 sections
Hydroxyzine HUMAN PRESCRIPTION DRUG LABEL 1 0904-0359 TABLET, FILM COATED 50 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6617 TABLET, FILM COATED 25 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6618 TABLET, FILM COATED 50 mg ORAL ANDA 13 sections